In older adults with type 2 diabetes receiving GLP‑1 receptor agonists (e.g., liraglutide, semaglutide, dulaglutide), does therapy increase the risk of osteoporosis or fracture/fall?

GLP-1 Receptor Agonists and Bone/Fall Risk in Older Adults with Type 2 Diabetes

GLP-1 receptor agonists do NOT increase osteoporosis or fracture risk in older adults with type 2 diabetes—in fact, the most recent high-quality evidence suggests they may reduce fracture risk compared to other diabetes medications. 1

Evidence Summary and Clinical Implications

Fracture Risk: Protective Effect in Type 2 Diabetes

The strongest and most recent evidence comes from a 2026 target trial emulation study of 133,606 adults with type 2 diabetes, which found that GLP-1 RA initiation was associated with a 21% reduction in fragility fracture risk compared to DPP-4 inhibitors (HR 0.79; 95% CI 0.76-0.83) 1. This protective effect was most pronounced for:

• Vertebral fractures: 32% risk reduction (HR 0.68)
• Hip/femur fractures: 30% risk reduction (HR 0.70)

Critically, this benefit was independent of weight loss or glycemic control improvements—the direct skeletal effect persisted even after accounting for changes in BMI and HbA1c 1. This suggests GLP-1 RAs have intrinsic bone-protective mechanisms beyond their metabolic effects.

Important Context: Diabetes Status Matters

A crucial finding from the same study: the fracture protection only occurred in patients WITH type 2 diabetes (HR 0.91), while those WITHOUT diabetes showed increased risk (HR 1.13; interaction P < 0.001) 1. This aligns with a 2026 obesity study showing no MOF benefit in people without T2D 2.

Clinical takeaway: For your specific population (older adults with T2D), GLP-1 RAs appear skeletal-protective, not harmful.

Contradictory Evidence Requires Careful Interpretation

One 2026 Israeli study of adults ≥65 years found an 11% increased fracture risk with GLP-1 RAs (HR 1.11; 95% CI 1.01-1.21) 3. However, this conflicts with:

• The larger US study showing protection 1
• A 2026 Danish nationwide study showing reduced fracture risk (OR 0.88 for MOF) 4
• A 2026 US study showing no increased upper extremity fracture risk 5

The Israeli study's findings may reflect population-specific factors, residual confounding, or different prescribing patterns in older adults. The weight of evidence, particularly the most methodologically rigorous target trial emulation, favors a protective or neutral effect.

Fall Risk Considerations

Direct Fall Risk from GLP-1 RAs

The evidence does NOT support increased fall risk from GLP-1 RAs themselves. Unlike medications that cause hypoglycemia (insulin, sulfonylureas) or orthostasis (SGLT2 inhibitors), GLP-1 RAs:

• Do not cause hypoglycemia as monotherapy 6
• Are not associated with volume depletion or orthostatic hypotension 6
• May improve cardiovascular outcomes, potentially reducing fall-related complications 7

Indirect Considerations

Weight loss-related concerns: While GLP-1 RAs cause substantial weight loss (including ~25-39% lean mass loss with newer agents like semaglutide/tirzepatide) 8, current evidence does not demonstrate this translates to increased fall or fracture risk in T2D populations 1.

Gastrointestinal effects: Nausea, vomiting, and diarrhea are common 7, 9, which could theoretically cause dehydration-related falls, but this is not documented as a significant clinical problem in the fracture literature.

Bone Mineral Density Effects

A 2026 RCT in adults with increased fracture risk found decreases in BMD at total hip and lumbar spine after 12 months of semaglutide, with elevated bone resorption markers 8. However, this BMD decline did NOT translate to increased fractures in the large observational studies 1, 4.

This paradox is explained by: Type 2 diabetes is associated with normal or high BMD that underestimates fracture risk 10. GLP-1 RAs may improve bone quality despite modest BMD reductions, similar to how diabetes patients fracture despite higher BMD.

Comparison to Other Diabetes Medications

Higher Risk Alternatives to AVOID:

• Thiazolidinediones (TZDs): Double fracture risk in women after 1-2 years (HR 2.23) 10
• Canagliflozin (SGLT2i): Associated with decreased hip BMD and increased arm/leg fractures 11
• Insulin/sulfonylureas: Increase hypoglycemia risk, which elevates fracture risk 52% (RR 1.52) 10

Safer Alternatives:

• Metformin: Neutral bone effects, first-line agent 6
• DPP-4 inhibitors: Neutral bone effects but less fracture protection than GLP-1 RAs 1

Practical Clinical Algorithm

For older adults with T2D considering GLP-1 RA therapy:

1. Assess baseline fracture risk using FRAX (if ≥40 years), BMD with VFA, and diabetes-specific factors 12, 10:

   • Diabetes duration >10 years
   • HbA1c >8%
   • Hypoglycemia history
   • Microvascular complications (neuropathy, retinopathy, nephropathy)

2. GLP-1 RAs are PREFERRED over TZDs, sulfonylureas, or canagliflozin in patients with moderate-to-high fracture risk 10, 11

3. Do NOT withhold GLP-1 RAs due to fracture concerns in T2D patients—they may be protective 1

4. Ensure adequate bone health support:

   • Calcium and vitamin D to meet RDA 12, 10
   • Weight-bearing exercise 12
   • Consider bisphosphonates or denosumab if T-score ≤-2.0 or prior fragility fracture 10

5. Minimize hypoglycemia risk by reducing insulin/sulfonylurea doses when adding GLP-1 RAs 9—hypoglycemia increases fall/fracture risk more than the GLP-1 RA itself 10

6. Monitor for GI side effects that could cause dehydration 7, 9, though this is not a documented fracture risk factor

Common Pitfalls to Avoid

• Don't confuse GLP-1 RA effects with SGLT2 inhibitor risks: SGLT2 inhibitors (especially canagliflozin) have documented fracture concerns 11, 13; GLP-1 RAs do not share this risk profile
• Don't extrapolate non-diabetes data to T2D patients: Fracture effects differ by diabetes status 1, 2
• Don't rely solely on BMD: In T2D, BMD underestimates fracture risk 10; clinical risk factors and FRAX are more informative
• Don't overlook hypoglycemia prevention: The greatest fall/fracture risk comes from hypoglycemia, not the GLP-1 RA itself 10

Guideline-Based Bone Health Management in T2D

The 2024 ADA Standards of Care emphasize 10:

• Screen BMD at least 5 years after T2D diagnosis, repeat every 2-3 years
• Prioritize medications with proven bone safety when selecting glucose-lowering agents
• Individualize glycemic targets to avoid hypoglycemia in high-fracture-risk patients
• Treat osteoporosis aggressively: Bisphosphonates or denosumab for T-score ≤-2.0 or prior fragility fracture

GLP-1 RAs align with these recommendations as they do not cause hypoglycemia, have favorable or neutral skeletal effects, and provide cardiovascular benefits 7, 6, 9.